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3Abstract
Introduction
Chronic breathlessness is a common and distressing symptom of advanced disease with few
effective treatments. Central nervous system mechanisms are important in respiratory sensation
and control. Consequently, drugs which may modify processing and perception of afferent
information in the brain, may have a role. Antidepressants have been proposed, however current
evidence is limited. Of potentially suitable antidepressants, mirtazapine is an attractive option given
its tolerability profile, low cost and wide availability, along with additional potential benefits.
Areas covered
The paper provides an overview of the physiology of breathlessness, with an emphasis on central
mechanisms, particularly the role of fear circuits and the associated neurotransmitters. It provides a
potential rationale for how mirtazapine may improve chronic breathlessness and quality of life in
patients with advanced disease. The evidence was identified by a literature search performed in
PubMed through to October 2018.
Expert commentary
Currently, there is insufficient evidence to support the routine use of antidepressants for chronic
breathlessness in advanced disease. Mirtazapine is a promising candidate to pursue, with definitive
randomised controlled trials required to determine its efficacy and safety in this setting.
Key words
chronic lung disease, chronic breathlessness, breathlessness perception, mirtazapine, antidepressant
41. Introduction
Breathlessness is a common and distressing symptom of advanced disease, affecting most people
living with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) [1, 2, 3].
Breathlessness is ‘a subjective experience of breathing discomfort that consists of qualitatively
distinct sensations that vary in intensity’[4]. Chronic breathlessness has recently been defined as
‘breathlessness that persists despite optimal treatment of the underlying pathophysiology and
results in disability for the patient’[5]. Refractory breathlessness is another term used to describe
breathlessness that persists despite optimal treatment of the underlying condition[6]. Chronic or
refractory breathlessness is often accompanied by episodic breathlessness, defined as ‘a severe
worsening of breathlessness intensity or unpleasantness beyond usual fluctuations in the patient’s
perception’[7].
Whilst non-pharmacological interventions take priority initially, the more severe the breathlessness
is, the more likely the need for pharmacological treatment[8, 9]. Currently no drugs are licenced for
chronic or refractory breathlessness[10]. The benefit of oxygen in the absence of hypoxia remains
unclear with evidence from larger trials required[11, 12], and whilst benzodiazepines are sometimes
used to treat breathlessness-related anxiety, there is no evidence that they relieve breathlessness
itself in people with advanced cancer and COPD[13]. There is evidence to support the use of parental
and oral opioids[14]. However, optimal dosing, titration and potential issues arising from long-term
use and safety remain to be determined[13, 15, 16, 17, 18]. Further, not all patients are suitable for,
want to take, or respond to opioids, and clinicians can be reluctant to prescribe them[17, 19, 20, 21,
22]. Thus, new effective treatments are required.
Breathlessness is multidimensional, comprising distinct sensory (intensity / qualitative) and
affective/cognitive components that can be manipulated and measured independently of each
other[23, 24, 25, 26]. Consequently, drugs which may modify processing and perception of afferent
information in the brain, may have a role. This may be a mechanism of action for opioids.
Antidepressants have been proposed, however current evidence is limited[27, 28, 29, 30, 31].
Recently published data found no benefit when sertraline (a selective serotonin reuptake inhibitor
antidepressant (SSRI)) was compared to placebo in patients with a Modified Medical Research
Council (mMRC) Dyspnea Scale grade of two or above[31]. Mirtazapine is a common antidepressant
which is acceptable in the advanced disease population. Its actions on multiple relevant
neurotransmitter systems distinguish it from other antidepressants, and this, alongside a favourable
side effect profile, make it a promising candidate to explore in the treatment of chronic
breathlessness.
5The paper reviews the physiology of breathlessness, with an emphasis on central mechanisms, in
particular the role of fear circuits, and the associated neurotransmitters. We consider how one
particular antidepressant, mirtazapine may improve chronic breathlessness and quality of life in
patients with advanced disease. The evidence was identified by searching for key terms in published
databases including PubMed through to October 2018. Additional papers were identified through
citation searches and expert opinion. Evidence was included based on the consensus of the research
team regarding quality and relevance to the review question. Whilst we recognise the relationship
between depression, anxiety and breathlessness[32, 33, 34, 35, 36, 37, 38, 39], exploring how
treatment of a concurrent mood disorder may affect chronic breathlessness is beyond the scope of
this paper. This paper focuses on how mirtazapine may affect the experience of breathlessness in
those both with, and without a mood disorder.
2. Mechanisms of breathlessness
2.1 Physiology
The mechanisms of breathlessness are complex and incompletely understood, but are thought to
encompass interactions between multiple physiological, psychological, social, and environmental
factors[4, 40]. There is evidence that qualitative appraisal of respiratory sensations is mechanistically
distinct to breathlessness intensity[23, 41].
Theories about breathlessness perception can generally be divided into two categories. In the first,
breathlessness is explained as being driven by cortical integration of an ascending copy of the
descending motor activity to respiratory muscles (the ‘neural respiratory drive’ (NRD)) together with
feedback from respiratory sensory afferents[4]. The second category presents the theory of
interoception, where the brain generates sensations (priors) based on expectations learnt from past
experience. These priors are then compared against incoming afferent signals to generate a
symptom experience[48].
Patient-reported breathlessness intensity in chronic respiratory disease has been shown to be
closely related to increased levels of NRD, reflecting the increased load on, and/or reduced capacity
of, the respiratory muscles as a consequence of impaired respiratory mechanics[42, 43, 44, 45].
These observations support the hypothesis that the perception of breathlessness intensity in
humans is mechanistically linked to the awareness of increased NRD as sensed by increased ‘central
6corollary discharge’, which refers to the simultaneous projection of resultant neural signals from the
motor cortex and/or respiratory centres of the brainstem to the respiratory muscles and sensory
areas of the brain[46, 47]. Distinct sensations of breathlessness, most importantly “work/effort”, “air
hunger” (“unsatisfied inspiration”/”urge to breathe”) and “chest tightness”, are however likely to
originate from central integration of differing sources of afferent information[4, 40, 45].
Neuroimaging studies are beginning to elucidate complex interactions between neural networks
underpinning emotional and sensory perception of breathlessness, offering important insights into
the role of higher cortical processing in respiratory sensation[48, 49, 50, 51, 52, 53]. Initial studies of
induced breathlessness in healthy volunteers have confirmed activation of the insula, amygdala and
anterior cingulate cortex, areas of the brain known to be active during perceived threat, with
processing of the affective unpleasantness of perceived dyspnea in the right anterior insula and
amygdala[48, 49, 50, 53]. In addition it has recently been shown that simply observing dyspnoea in
others can elicit dyspnoea, negative affect and increased brain responses in the absence of
physiological changes[54]. This supports the idea that central brain processes can elicit or intensify
the experience breathlessness. More recently, studies have included people with chronic lung
disease. A feasibility study of magnetoencephalography scanning found increased β band activity 
indicating constant ‘vigilance’, or an anticipatory state with regard to peripheral respiratory
stimuli[55], and preliminary findings from a fMRI feasibility study suggest that the degree of
disconnection between the left anterior insula and dorsal anterior cingulate cortex correlates with
unpleasantness/discomfort of breathlessness (Meng D, Cottam W, Weller J, et al. European Society
of Radiology Congress; 2018; Vienna, Austria).
2.2 Fear circuits and the perception of threat
The regions identified in the above studies closely relate to neurological circuits involved in threat
perception and the experience of fear[48, 50, 53]. The ability to perceive threat is vital for survival.
The response to threat is multi-faceted and regulated by numerous neuronal connections entering
and leaving the amygdala (Figure 1). These pathways are responsible for the motor and endocrine
features of the ‘fight or flight response’, combined with the conscious perception of fear[56, 57]. The
fight or flight response is mediated by neuronal transmission from the amygdala to the
periaqueductal grey area. Ongoing transmission to the hypothalamus and areas of the brainstem
results in a rapid release of cortisol, and an autonomic response is triggered by the locus coerulus
which can include an increase in heart rate and blood pressure[57]. The emotional response to a
7threat involves neural transmission between the amygdala, the orbitofrontal cortex and the anterior
cingulate cortex [58]. Given the potential role of fear circuits in the perception of breathlessness,
drugs acting within these regions such as mirtazapine may be beneficial. This is further discussed in
section 3.2.
Whilst fear is often experienced and forgotten, the amygdala assimilates stimuli associated with
previous fearful situations, and when exposed to this stimuli again, triggers a response (fear
conditioning)[57]. This could explain how an episode of breathlessness and severe panic may lead to
recurrent panic when the patient is exposed to a similar trigger. During interoception the brain
generates sensations referred to as priors based on expectations learnt from a past experience.
These priors are then compared against incoming afferent signals to generate a symptom
experience[59]. These interactions can be influenced by many factors including fatigue and
depression[60], and recent work has demonstrated how a rehabilitation programme for
breathlessness can lead to changes in associative learning and the resetting of breathlessness
related priors[61]. A number of other factors have been associated with an increased perception of
threat including the environment, psychiatric illness, and personality traits[62, 63, 64, 65].
82.3 The function of neurotransmitters in breathlessness
A number of neurotransmitters have been identified as important in breathlessness, in particular,
serotonin (5-HT) and norepinephrine (NE). Other neurotransmitters (GABA, dopamine, acetylcholine
and NMDA) may also play roles in symptom perception through their contribution to interoceptive
processes.
5-HTplays a role in the central control of respiration via multiple receptor subtypes, contributing to
chemosensitivity and mediating ventilatory response to changes in CO2/pH, and by maintaining
regulatory function as part of respiratory neuroplasticity[66, 67, 68, 69, 70, 71, 72]. 5-HT also
regulates anxiety and panic through connections between the amygdala, and the prefrontal cortex,
striatum and thalamus, and may therefore be important in the conscious perception of
breathlessness[73]. An inhibitory effect on the amygdala results in suppression of fear circuits and
thus drugs which increase 5-HT can reduce levels of anxiety and panic [57, 74]. Further, the
importance of serotonergic modulation is suggested by a reduction in panic following administration
of L-5-hydroxytryptophan (the immediate precursor of 5-HT), sertraline or citalopram to patients
with panic disorder breathing a mixture containing 35% CO2 [75, 76]. However, despite strong
evidence of the role of serotonin in respiration, clinical benefit has not yet been demonstrated[31].
NE is important in neuronal connections between the amygdala and the locus coeruleus, the centre
involved in generating the physiological response to stress and panic, e.g. increased heart rate,
blood pressure and respiratory rate[57]. Whilst the role of NE during an acute stress is hyperactivity,
chronic stress (for example in mood disorders) causes hypo-reactivity of the NE system[77], and in
animal studies exposure to chronic stress has been correlated with a decrease in the release of NE in
the brain, as well as atrophy of NE axonal projections[78, 79]. Further, venoarterial levels of NE and
3-methoxy-4-hydroxyphenylglycol (the metabolite of NE) are significantly lower in people diagnosed
with depression compared to controls[80]. In addition a rise in circulating norepinephrine causes
relaxation of bronchial muscles and a decrease in fluid secretion from bronchial glands therefore
improving respiration[81, 82]. Other neurotransmitters of interest include endorphins[83],
cannabinoids and neurokinin[84].
93. Mirtazapine for chronic breathlessness
3.1 Mechanism of action
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) which is well
tolerated, relatively cheap and available in generic form worldwide[85, 86, 87]. Mirtazapine
antagonizes α2 auto- and hetero-receptors resulting in enhanced noradrenergic transmission and
reduced inhibition of 5-HT release (Figure 2)[88, 89]. NE release in the raphe nuclei also stimulates
postsynaptic α1 receptors of neuronal cell bodies, causing 5-HT release from downstream axon
terminals such as those in the cortex (Figure 2)[57]. This enhanced noradrenergic and serotonergic
transmission is mostly responsible for the antidepressant and anxiolytic effects of mirtazapine.
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Mirtazapine also antagonizes 5-HT2 and 5-HT3 receptors and as a consequence, unlike with SSRIs,
gastro-intestinal effects (e.g. nausea, diarrhoea) and sexual dysfunction are uncommon[89]. It is a
potent antagonist of histamine H1 receptors[88] explaining the most common side effects of
somnolence, increased appetite and weight gain[86]. At higher doses, sedation is less commonly
reported, possibly due to increased noradrenergic transmission counteracting the antihistamine
effect. It is not known to be associated with a reduced respiratory drive which is an advantage in
chronic lung disease management[90]. It is worth noting that mirtazapine is metabolized by CYP1A2,
CYP2D6, and CYP3A4 and caution should be taken with concurrent use of drugs which inhibit or
induce these enzymes. This should be considered in a population likely to have high levels of
comorbidity and polypharmacy[91].
Mirtazapine is authorised for the treatment of depression; additional beneficial effects on anxiety,
psychological distress and sleep disturbance are seen compared with placebo[92]. Mirtazapine is
significantly more effective at treating depression at two weeks compared to selective serotonin
reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) [93]. A
systematic review and meta-analysis of the efficacy and acceptability of 21 antidepressant drugs in
adults with depression found that mirtazapine had a higher response rate and lower dropout rate
than the other antidepressants when compared with placebo[85]. Although an anxiolytic effect has
been demonstrated for mirtazapine[94], it is not currently authorised for the treatment of anxiety
disorders. It is however, free from the initial worsening of anxiety or agitation that can occur with
SSRIs.
3.2 Mirtazapine as a treatment for breathlessness and other symptoms in chronic lung
disease
Mirtazapine may benefit chronic breathlessness indirectly through known effects on mood.
However, mirtazapine may also have direct beneficial effects, through inhibition of fear circuits and
fear conditioning, and by causing bronchodilation. Even in healthy volunteers, mirtazapine has rapid
effects. Two hours after a single dose of mirtazapine, there are changes in keeping with a decreased
processing of threatening stimuli, an increased processing of positive or rewarding stimuli and
reduced self-referential processing[95, 96, 97, 98]. At the neural level, there are decreased right
amygdala-hippocampal and fronto-striatal responses to fearful vs. happy facial expressions,
increased responses of the parietal cortex to a reward task, and reduced responses in the
dorsomedial prefrontal cortex, ventromedial prefrontal cortex and ventral anterior cingulate cortex,
considered the self-referential network[95, 97, 98]. In response to more natural and complex
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emotional stimuli, mirtazapine leads to large-scale changes spanning limbic, sensorimotor and
cortical midline structures[99]. Taken together, these changes suggest that mirtazapine impacts
rapidly on neural circuits involved in vigilance and the perception of, and the emotional response to,
unpleasant stimuli (of which breathlessness is one) through the process of interoception.
In addition mirtazapine may benefit additional symptoms common in this population. Mirtazapine is
a potent antagonist of histamine and therefore common side effects including somnolence,
increased appetite and weight gain may be of benefit to patients with chronic lung disease who
frequently report sleep disturbance, poor appetite and weight loss[86, 88, 100, 101]. Further,
depression, anxiety and panic are common in this group, and associated with increased healthcare
utilisation[32, 33, 34, 35, 36, 37, 38]. Generally, mood disorders are underdiagnosed and thereby
undertreated in the medically ill. In a large study of 1334 people with chronic lung disease, 80%
screened positive for depression, anxiety or both, yet only 31% were receiving treatment for anxiety
or depression[39]. Thus, by treating an underlying anxiety or depressive mood disorder, mirtazapine
may have beneficial effects on the emotional and behavioural response to chronic
breathlessness[57].
Conclusions
In addition to its known effects on mood, Mirtazapine has effects that are potentially beneficial for
the management of chronic breathlessness, predominantly by modifying the processing and
perception of afferent information in the brain. Mirtazapine is an attractive candidate to explore as
is well-tolerated, affordable and available, with a quick onset of action. Antagonism of 5-HT2 and 5-
HT3 receptors means mirtazapine does not share some of the common side effects of other
commonly used antidepressants, and antagonism of H1 receptors can result in improved appetite
and sleep which may be beneficial in patients with advanced disease. High quality evidence from
definitive randomised controlled trials is needed to determine the effectiveness of mirtazapine, on
the distressing and common symptom of chronic or refractory breathlessness.
Expert Commentary
Chronic breathlessness remains a common and distressing symptom of advanced disease with few
effective treatment options. Whilst there is evidence to support the use of parental and oral opioids,
not all patients report benefit, and long term safety data is currently lacking. The goal should be to
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identify new effective treatments so that clinicians and patients have more options. In recent years
thinking has moved towards drugs which may modify the processing and perception of afferent
information in the brain, such as antidepressants. The repurposing of existing inexpensive
medications that are off patent and widely available is an attractive option, however, data remains
limited. Mirtazapine is a promising candidate, but there is currently insufficient evidence to support
use to treat breathlessness in clinical practice. The concern is that clinicians may nevertheless opt to
give antidepressants including mirtazapine for chronic breathlessness, particularly as they are
inexpensive and off patent. It is important to ensure that patients are not being given medicines that
are ineffective in treating breathlessness. Blinded randomised controlled trials are therefore
urgently needed to provide appropriate evidence on the effectiveness of mirtazapine in reducing
breathlessness in patients with and without depression and anxiety.
Five-year view
In the next 5 years we anticipate that blinded randomised trials will be conducted to determine the
effectiveness of antidepressants including mirtazapine to treat chronic breathlessness. Results of
these trials will aid national and international clinical guidelines and policy recommendations by
providing a much needed evidence base.
Key issues
 Chronic breathlessness remains a common and distressing symptom of advanced disease
with few effective treatment options
 Whilst there is evidence to support the use of parental and oral opioids, not all patients
report benefit, and long term safety data is currently lacking
 Therefore new effective treatments are urgently needed
 In recent years thinking has moved towards drugs which may modify the processing and
perception of afferent information in the brain, such as antidepressants
 Mirtazapine is a promising candidate, but there is currently insufficient evidence to support
routine use to treat breathlessness in clinical practice
 Definitive randomised controlled trials are needed to provide evidence to guide clinical
practice
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